Merck has patented genetic markers on chromosome 6 linked to improved responses to treatments targeting Clostridium difficile toxin B. The patent includes methods for identifying suitable patients for ...

Further evaluation revealed that these nanoparticles could facilitate the detection of Clostridium difficile Toxin B visually at an extremely low concentration (1 ng/mL) without the requirement for ...

difficile Toxin B, indicated to reduce the recurrence of ... This report provides a detailed market assessment of ZINPLAVA for clostridium difficile infection in the seven major markets, i.e ...

Proton pump inhibitors (PPIs), although introduced 25 years ago, still find their relevance in modern clinical practice settings and have been widely used in the management of acid-peptic diseases.[1] ...

The main pathogenic toxins of Clostridium difficile are toxin A (TcdA) and toxin B (TcdB). TcdB is the main pathogenic factor of Clostridium difficile infection. This review revealed the pathogenic ...

Rac1 small GTPase oscillations are anti‐phasic between mouse and human enteroids, regulating distinct necrotic cell death responses to Clostridium difficile toxin B. Schematic summary for establishing ...

Published today in Nature Structural & Molecular Biology, the study titled, "Structure of the full-length Clostridium difficile toxin B," sheds light on the weaknesses of TcdB, one of the toxins ...

Published today in Nature Structural & Molecular Biology, the study titled, "Structure of the full-length Clostridium difficile toxin B," sheds light on the weaknesses of TcdB, one of the toxins ...

Published today in Nature Structural & Molecular Biology, the study titled, "Structure of the full-length Clostridium difficile toxin B," sheds light on the weaknesses of TcdB, one of the toxins ...

The poster builds on the results of First Light's peer-reviewed paper, ' A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples ' in Nature ...